REM Sleep Behavior Disorder for Synucleinopathy Research
(NAPS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to prepare for future studies on treatments that protect against synucleinopathies, brain disorders linked to proteins. It focuses on individuals with idiopathic REM sleep behavior disorder (RBD), where people act out their dreams due to abnormal sleep patterns. Those with this condition, without a known cause like Parkinson's or narcolepsy, might be suitable candidates. The goal is to better understand the condition to develop effective treatments later.
As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking advancements in treatment.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
Why are researchers excited about this trial?
The North American Prodromal Synucleinopathy Consortium is unique because it aims to better understand the early stages of synucleinopathies, like Parkinson's disease. Researchers are excited about this trial because it holds the potential to identify early biomarkers and progression patterns, which are not well-defined in current treatment approaches. This could lead to earlier diagnosis and more targeted interventions, potentially slowing the disease's progression before symptoms become severe.
Who Is on the Research Team?
Bradley Boeve, MD
Principal Investigator
Mayo Clinic
Yo-El Ju, MD
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo a ~2-hour clinical assessment including medical history, physical exam, questionnaires, and blood draw. Optional lumbar puncture at select sites.
Data Collection
Standardized clinical assessments and biofluids are collected to develop biomarkers for synucleinopathies.
Follow-up
Participants are monitored for safety and effectiveness after data collection
What Are the Treatments Tested in This Trial?
Interventions
- NA
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Portland VA Medical Center
Collaborator
University of California, Los Angeles
Collaborator
Massachusetts General Hospital
Collaborator
National Institute on Aging (NIA)
Collaborator
Stanford University
Collaborator
Banner Health
Collaborator
Emory University
Collaborator
McGill University
Collaborator
University of Minnesota
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.